Skip to main content
Research

Not Expensive Enough – Prices for Over 30 Brand Drugs Increased This July

Tori Marsh, MPHJeroen van Meijgaard, PhD
Written by Tori Marsh, MPH | Analysis by Jeroen van Meijgaard, PhD
Published on July 17, 2019

In true drug-pricing fashion, on July 1, more drugs increased in price. In total, 37 brand drugs increased in list price—by as much as 20%.

Introduction

The list price is the official price that is set by the manufacturer. While few people pay the list price of the drug, the price is  a good marker for how much the drug costs.

Most of the drugs that increased in price are specialty drugs that few people take. But the majority of them were already expensive and only continue to increase in price.

Here are some common brand-name drugs whose prices went up on July 1.

July price bumps aren’t new

While unfortunate, these price changes are expected. Every year, some manufacturers increase the price of their drugs at the beginning and middle of the year—around January 1 and July 1. 

For instance, this past January, 486 drugs increased by an average of 5.2%, and this July, exactly six months later, 37 brand drugs increased by an average of 4.3%. These percentages are no coincidence, and they are actually part of a common drug manufacturer pricing strategy.  

Xermelo, for example, is manufactured by Lexicon Pharmaceuticals and is used to treat symptoms of carcinoid tumors. On January 1, 2019, Lexicon increased the price for Xermelo by 4.9%, and exactly six monthly later Xermelo increased by another 4.9%. So this year so far, Xermelo has increased by 9.8% in total. 

Back in 2019, some manufacturers pledged to keep their yearly price hikes under 10%, and since then, price increases for many drugs have averaged around 9.9%. But instead of  increasing the price of their drug by 9.9% once a year, some manufacturers attempt to fly under the radar and increase their drug’s price by around 5% twice a year.

– – –

Co-contributor: Jeroen van Meijgaard, PhD

Methodology: Prices in this analysis are the list price, which is the price the pharmaceutical company assigns as an official price for a drug, as of July 15. This list excludes any generic medications, over-the-counter medications, and medications that are administered under the supervision of a healthcare provider.

why trust our exports reliability shield

Why trust our experts?

Tori Marsh, MPH
Written by:
Tori Marsh, MPH
Tori Marsh is GoodRx’s resident expert on prescription drug pricing, prescribing trends, and drug savings. She oversees the GoodRx drug database, ensuring that all drug information is accurate and up to date.
Dr. van Meijgaard is a health economist with over 20 years of experience in healthcare informatics and has a knack for distilling meaningful insights from data. With extensive expertise in population research and the social, economic, and environmental determinants of health, Dr. van Meijgaard has published in leading academic journals.

Was this page helpful?

Latest articles